Kamada - KMDA Stock Forecast, Price & News

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Kamada Stock Performance

Shares of NASDAQ:KMDA traded down $0.11 during midday trading on Tuesday, reaching $5.17. 28,432 shares of the company were exchanged, compared to its average volume of 24,487. The company has a current ratio of 2.75, a quick ratio of 1.22 and a debt-to-equity ratio of 0.09. Kamada has a 1 year low of $4.22 and a 1 year high of $6.96. The stock has a fifty day simple moving average of $4.70 and a 200 day simple moving average of $5.23. The stock has a market cap of $230.17 million, a P/E ratio of -34.46 and a beta of 0.98.

Kamada (NASDAQ:KMDA - Get Rating) last released its quarterly earnings results on Tuesday, May 17th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.07). Kamada had a negative return on equity of 3.44% and a negative net margin of 6.31%. The company had revenue of $28.09 million for the quarter, compared to analysts' expectations of $32.43 million. During the same period in the prior year, the business earned $0.06 EPS. On average, research analysts forecast that Kamada will post -0.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KMDA has been the topic of several research reports. TheStreet lowered Kamada from a "c-" rating to a "d" rating in a report on Monday, June 13th. StockNews.com initiated coverage on Kamada in a report on Tuesday. They set a "buy" rating on the stock.